Long-acting growth hormone: An updated Growth Hormone Research Society consensus statement

Clicks: 20
ID: 327037
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #82 of 121 articles by views in european journal of endocrinology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 121 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Long-acting growth hormone (LAGH) preparations have moved from development to routine clinical use over the past decade. Several products are now approved for paediatric growth hormone deficiency (GHD), selected non-GHD short-stature indications, and, in some regions, for adult GHD. The Growth Hormone Research Society convened an international workshop in October 2025 to reappraise the evidence base and refine clinical recommendations. Currently, data are available for up to 7 years of LAGH treatment in over 8,000 individuals. This remains substantially shorter and smaller than for daily GH. Across preparations, short- to mid-term efficacy appears comparable to daily somatropin, provided dosing is individualised and monitored appropriately. Approvals and pivotal trials include both, treatment initiation and switching from daily GH, depending on product and regional label. No new major safety signals have been identified in trials and real-world reports, although data on BMI trajectories require further evaluation. Injection-site reactions remain the most frequent adverse event and vary by formulation. Anti-drug-antibodies have been observed, yet evidence suggests they have limited clinical impact. Effects on glucose metabolism resemble those of daily therapy, but metabolically high-risk groups are under-represented in studies. Among cancer survivors, data on tumour recurrence and second neoplasms with LAGH are not yet available. Recommendations and practice points emphasised careful patient selection and counselling, product-specific dosing, and insulin-like growth factor-I (IGF-I) monitoring. Urgent knowledge gaps include transition care, long-term efficacy, adherence and safety in cancer survivors. Well-resourced registries are essential for addressing these gaps and supporting safe, effective, and patient-centred use of LAGH.
Reference Key
openalex_W7204923899 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Katharina Schilbach, Peter Clayton, Nidhi Agrawal, Mai Christiansen Arlien-Søborg, Philippe Backeljauw, Beverly M. K. Biller, César Luiz Boguszewski, Margaret Cristina da Silva Boguszewski, Philippe Chanson, Pierre Chatelain, Stefano Cianfarani, Maria Fleseriu, Judith Gebauer, Adda Grimberg, Ken K. Y. Ho, Andrew R. Hoffman, Gudmundur Johannsson, Jens Otto Lunde Jørgensen, Anders Juul, Wolfram Karges, Jan Lebl, Xiaoping Luo, Mohamad Maghnie, Aristides K Maniatis, Bradley S. Miller, Sebastian Neggers, Michel Polak, Sally Radovick, Lars Sävendahl, Júnia Ribeiro de Oliveira Longo Schweizer, Paulo Ferrez Collett‐Solberg, Adam Stevens, Christian J. Strasburger, Christa C. van Bunderen, Haim Werner, Joachim Woelfle, Kevin C J Yuen, Martin Bidlingmaier
Are you one of these authors? Claim your profile
Journal european journal of endocrinology
Year 2026
DOI
10.1093/ejendo/lvag167
URL
https://academic.oup.com/ejendo/advance-article-pdf/doi/10.1093/ejendo/lvag167/70888905/lvag167.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.